11
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Rheumatologists’ knowledge and perception of COVID-19 and related vaccines: the vaXurvey2 online survey

      research-article
      1 , , 2 , 3 , 3 , 4 , 5 , 5 , 6 , 7 , 8 , 2 , 2 , 9 , 10 , 11 , 11 , 12 , 13 , 14 , 14 , 15 , 16 , 2 , 17 , 18 , 2 , 2 , 2 , 4 , The Egyptian College of Rheumatology (ECR) COVID-19 Study Group
      Rheumatology International
      Springer Berlin Heidelberg
      COVID-19, Infection, Vaccine, Adverse effects, World pandemic, Rheumatologists

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The study aimed to explore the experience of coronavirus disease-2019 (COVID-19) infection and vaccine adverse events (AEs) among rheumatologists. A validated questionnaire was distributed as a Google form to rheumatologists across the country via social networking sites from late December 2021 till early January 2022. The questionnaire included questions regarding participants' socio-demographic details, COVID-19 infection and vaccination details with special emphasis on AEs. Out of 246 responses, 228 were valid. 200 (81.3%) responders had received the vaccine. The mean age of the 228 participants was 37.9 ± 8.5 years, 196 were females and 32 males (F:M 6.1:1) from 18 governorates across the country. Comorbidities were present in 54 subjects (27%). There was a history of highly suspicious or confirmed COVID-19 infection in 66.7% that were all managed at home. The COVID-19 vaccine was received by 200 and a booster dose of 18.5%. Obesity and musculoskeletal involvement co-morbidities were present only in those with AEs (9.1% and 5.5% respectively). AEs were present in 82%; 66.7% had injection-site tenderness, 50% fatigue, 35.5% fever, 15% chills, 42.5% myalgia, 14.5% arthralgia, 8% low back pain, headache 31%, dizziness 10%, sleepliness 16% and 15% developed post-vaccine. There were no differences according to the geolocation regarding the occurrence of COVID-19 infection ( p = 0.19) or AEs post-vaccine ( p = 0.58). The adverse events were mostly mild to moderate and tolerable which makes this work in agreement with other studies that support the broad safety of the vaccine in favor of the global benefit from mass vaccination.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s00296-022-05130-3.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

          Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Improving the Quality of Web Surveys: The Checklist for Reporting Results of Internet E-Surveys (CHERRIES)

            Analogous to checklists of recommendations such as the CONSORT statement (for randomized trials), or the QUORUM statement (for systematic reviews), which are designed to ensure the quality of reports in the medical literature, a checklist of recommendations for authors is being presented by the Journal of Medical Internet Research (JMIR) in an effort to ensure complete descriptions of Web-based surveys. Papers on Web-based surveys reported according to the CHERRIES statement will give readers a better understanding of the sample (self-)selection and its possible differences from a “representative” sample. It is hoped that author adherence to the checklist will increase the usefulness of such reports.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Surveillance for Adverse Events After COVID-19 mRNA Vaccination

                Bookmark

                Author and article information

                Contributors
                h.fathi@yahoo.com
                imanalgazzar@hotmail.com
                miaa_a11@yahoo.com
                Dr.enas2000@gmail.com
                drnadagamal80@gmail.com
                Faten_ismail70@yahoo.com
                rawhyaelshereef@yahoo.com
                samartharwat2000@mans.edu.eg
                Shereenabdelsalam80@yahoo.com
                dr.nermeen81@gmail.com
                nohabaki@yahoo.com
                norayousry@kasralainy.edu.eg
                d_amani75@mans.edu.eg
                dr.moshrif@azhar.edu.eg
                yousrahisham@gmail.com
                dr.marwa.abdullah@gmail.com
                maha_emad83@yahoo.com
                Nohakhalil2007@gmail.com
                soha_eldessouki@yahoo.com
                nouran_abaza@med.asu.edu.eg
                amira.elshanawany@med.menofia.edu.eg
                emanfekry.8@azhar.edu.eg
                nehalhamdy7@gmail.com
                neveenayoub@yahoo.com
                bebo_sh@yahoo.com
                samarfawzy1@yahoo.com
                Dr.safaasayed@gmail.com
                gheitamer@hotmail.com
                nevin_hammam@hotmail.com
                Journal
                Rheumatol Int
                Rheumatol Int
                Rheumatology International
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0172-8172
                1437-160X
                16 April 2022
                : 1-10
                Affiliations
                [1 ]GRID grid.411170.2, ISNI 0000 0004 0412 4537, Rheumatology Department, Faculty of Medicine, , Fayoum University, ; Fayoum, Egypt
                [2 ]GRID grid.7776.1, ISNI 0000 0004 0639 9286, Rheumatology Department, Faculty of Medicine, , Cairo University, ; Cairo, Egypt
                [3 ]GRID grid.411662.6, ISNI 0000 0004 0412 4932, Rheumatology Department, Faculty of Medicine, , Beni Suef University, ; Beni Suef, Egypt
                [4 ]GRID grid.252487.e, ISNI 0000 0000 8632 679X, Rheumatology Department, Faculty of Medicine, , Assuit University, ; Assuit, Egypt
                [5 ]GRID grid.411806.a, ISNI 0000 0000 8999 4945, Rheumatology Department, Faculty of Medicine, , Minia University, ; Minia, Egypt
                [6 ]GRID grid.10251.37, ISNI 0000000103426662, Internal Medicine Department, Faculty of Medicine, , Rheumatology Unit, Mansoura University, ; Mansoura, Egypt
                [7 ]GRID grid.412258.8, ISNI 0000 0000 9477 7793, Rheumatology Department, Faculty of Medicine, , Tanta University, ; Tanta, Egypt
                [8 ]GRID grid.7269.a, ISNI 0000 0004 0621 1570, Internal Medicine Department, Faculty of Medicine, , Rheumatology Unit, Ain Shams University, ; Ain Shams, Egypt
                [9 ]GRID grid.10251.37, ISNI 0000000103426662, Rheumatology Department, Faculty of Medicine, , Mansoura University, ; Mansoura, Egypt
                [10 ]GRID grid.411303.4, ISNI 0000 0001 2155 6022, Rheumatology Department, Faculty of Medicine, , Azhar University, ; Assiut, Egypt
                [11 ]GRID grid.7155.6, ISNI 0000 0001 2260 6941, Rheumatology Department, Faculty of Medicine, , Alexandria University, ; Alexandria, Egypt
                [12 ]GRID grid.33003.33, ISNI 0000 0000 9889 5690, Rheumatology Department, Faculty of Medicine, , Suez Canal University, ; Ismailia, Egypt
                [13 ]GRID grid.7776.1, ISNI 0000 0004 0639 9286, Internal Medicine Department, Rheumatology and Immunology Unit, Faculty of Medicine, , Cairo University, ; Cairo, Egypt
                [14 ]GRID grid.7269.a, ISNI 0000 0004 0621 1570, Rheumatology Department, Faculty of Medicine, , Ain Shams University, ; Ain Shams, Egypt
                [15 ]GRID grid.411775.1, ISNI 0000 0004 0621 4712, Rheumatology Department, Faculty of Medicine, , Menoufia University, ; Menoufia, Egypt
                [16 ]GRID grid.411303.4, ISNI 0000 0001 2155 6022, Internal Medicine Department, Faculty of Medicine, , Rheumatology Unit, Azhar University, ; Ain Shams, Egypt
                [17 ]GRID grid.415762.3, Rheumatology Department, , Berket Elsabaa Hospital, Ministry of Health, ; Menoufia, Egypt
                [18 ]GRID grid.252487.e, ISNI 0000 0000 8632 679X, Rheumatology Department, , Assiut University Student Hospital, ; Assiut, Egypt
                Article
                5130
                10.1007/s00296-022-05130-3
                9012992
                eeb30bcc-701d-419d-ba4c-705620ba0aec
                © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                Categories
                Observational Research

                Rheumatology
                covid-19,infection,vaccine,adverse effects,world pandemic,rheumatologists
                Rheumatology
                covid-19, infection, vaccine, adverse effects, world pandemic, rheumatologists

                Comments

                Comment on this article